Join
Live feed
·
PRReleasevia Quantisnow
Prime Medicine Inc. logo

Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

ByQuantisnow·Wall Street's wire, on your screen.
PRME· Prime Medicine Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PRME (Prime Medicine Inc.) and more on Quantisnow.